Biotechnology and biomanufacturing among the most promising technology fields of this century, according to the EU Commission
(Berlin – March 20, 2024) The EU Commission today published its communication entitled “Building the future with nature: Boosting Biotechnology and Biomanufacturing in the EU”. In it, biotechnology and biomanufacturing are identified as one of the most promising technology fields of this century and numerous measures are outlined that should make Europe a strong biotechnology location. The biotechnology industry association BIO Deutschland expressly welcomes this paper by the EU Commision. The analysis of the status quo and the actions derived from it can help Europe to benefit extensively from the key technology of biotechnology and to become an international leader.
Oliver Schacht, Chairman of the Board of BIO Deutschland, explains: “We are pleased that the European Commission has recognized the outstanding importance of biotechnology and bioproduction and has finally made a clear commitment to it. The communication published today describes the great potential of biotechnology, identifies weaknesses in European biotechnology policy, and makes important proposals for how the latter can be remedied. An EU Biotech Hub to help companies navigate the various regulations may be useful. However, it is more important to bring the regulations up to date with the latest scientific findings, to reduce red tape and ideally to digitalize them. The Commission is also rightly addressing this issue and even proposes an EU Biotech Act. We would like to see the German government make an equally clear commitment to biotechnology. For years, we have been proposing a biotechnology agenda for Germany to better position our promising industry internationally.”
The achievements of the German biotechnology industry and the framework conditions that need to be adapted as a matter of priority in Germany will also be discussed at the German Biotechnology Days, which will take place at the bcc in Berlin on April 16 and 17, 2024. www.biotechnologietage.de
About BIO Deutschland:
BIO Deutschland e. V., based in Berlin, has around 380 members – companies, BioRegions and industry service providers – and aims to support and promote the development of an innovative industry in Germany based on modern life sciences. Oliver Schacht, Ph. D., is chairman of the board of BIO Deutschland.
Further information is available at: www.biodeutschland.org
BIO Deutschland's supporting members and industry partners are:
AGC Biologics, Avia, Baker Tilly, Bayer, BioSpring, Boehringer Ingelheim, BüchnerBarella, Centogene, Citeline, CMS Hasche Sigle, Deutsche Bank, Ernst & Young, Evotec, KPMG, Lonza, Miltenyi Bi otec, MorphoSys, Novartis, Pfizer, PricewaterhouseCoopers, QIAGEN, Rentschler Biopharma, Roche Diagnostics, Sanofi Aventis Deutschland, Simmons & Simmons, Thermo Fisher Scientific, SpringerNature, Vertex Pharmaceuticals, Vibalogics, ZETA.
Contact:
BIO Deutschland e. V.
Dr. Claudia Englbrecht
Schützenstraße 6a
10117 Berlin
Tel.: +49 30 2332 164-32
Mobile: +49 151 14067326
E-Mail: englbrecht@biodeutschland.org